According to the GLOBOCAN 2022 report, a sharp rise in cancer cases has been observed, i.e
The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day
The COVID-19 vaccine product CPT codes for 2025-2026 are as follows: 91319 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ) 91320 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ) 91321 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use ) 91322 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use ) 91323 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use ) 91304 ( Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use ) Note: Code 91323 is marked as a new code in the 2026 CPT code set because the code was added during the July 2025 code changes, and it will be featured in the CPT code book for the first time with the 2026 edition
The most common side effects are extremely mild and infrequent, primarily involving occasional skin irritation, mild redness, or transient tingling sensation in a small percentage of users, typically resolving without intervention and not requiring discontinuation
